Q2 2026 13F · SEC CIK 1839948

TCG Crossover Management, LLC

Hedge fundFiled 2026-08-14 for Q2 2026. Open the filing ↗ · All SEC filings ↗

Reported 13F value: $4.2B
Reported positions: 54
Top holdings a year, 3 yrs: +69.9%
Assets under management: $5.1B

TCG Crossover Management, LLC is a hedge fund that reported 54 positions worth $4.2B in its Q2 2026 13F, filed 2026-08-14. Its largest holdings were Abivax SA (ABVX, 19.2%), Tango Therapeutics Inc (TNGX, 6.8%), Cg Oncology Inc (CGON, 6.3%). A portfolio copying its top holdings returned 69.9% a year over the last 3 years, against 21.8% for the S&P 500.

TCG Crossover Management, LLC holdings largest 50 of 54 positions.

Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.

TCG Crossover Management, LLC 13F holdings
Stock	% of 13F value	Q1 2026	Shares	Share change	Reported value
ABVXAbivax SA	19.2%	20.6%	6,007,834	-7.3%	$800.6M
TNGXTango Therapeutics Inc	6.8%	6.3%	9,081,201	-13.8%	$283.9M
CGONCg Oncology Inc	6.3%	7.1%	3,670,206	+0.0%	$260.8M
COGTCogent Biosciences Inc	4.5%	5.4%	4,854,436	-1.9%	$187.9M
IMVTImmunovant Inc	4.1%	3.2%	4,457,988	+0.0%	$171.8M
SYRESpyre Therapeutics	4.1%	2.7%	1,900,582	+0.0%	$168.7M
DNTHDianthus Therapeutics Inc	3.9%	4.0%	1,676,624	+0.0%	$163.4M
MIRMMirum Pharmaceuticals Inc	3.0%	2.8%	1,062,049	+0.0%	$124.3M
ZLABZai Lab Ltd	2.8%	New	6,137,627	—	$116.6M
AMLXAmylyx Pharmaceuticals Inc	2.7%	2.5%	6,243,812	+0.0%	$112.1M
GLUEMonte Rosa Therapeutics Inc	2.7%	2.2%	4,622,151	+0.0%	$111.9M
BCRXBiocryst Pharmaceuticals Inc	2.6%	3.0%	11,020,968	+0.0%	$110.2M
VORVor Biopharma Inc	2.5%	2.8%	5,673,078	+0.0%	$104.4M
TYRATyra Biosciences Inc	2.5%	3.6%	3,248,980	+0.0%	$103.8M
DYNDyne Therapeutics Inc	2.5%	2.4%	4,615,144	+0.0%	$102.5M
IRONDisc Medicine Inc	2.4%	2.5%	1,341,862	+0.0%	$98.1M
RLAYRelay Therapeutics Inc	1.9%	1.2%	4,273,356	+0.0%	$80.0M
SVRASavara Inc	1.8%	1.9%	12,362,205	+0.0%	$76.2M
AURAAura Biosciences Inc	1.6%	New	9,533,333	—	$67.7M
RVMDRevolution Medicines Inc	1.5%	1.6%	340,899	-40.9%	$63.8M
TRAXFirst Tracks Biotherapeutics	1.4%	New	2,895,304	—	$58.3M
KODKodiak Sciences Inc	1.4%	1.6%	1,445,538	+0.0%	$56.3M
AVTXAvalo Therapeutics Inc	1.3%	0.3%	3,017,120	+308.6%	$55.8M
LBRXLB Pharmaceuticals, Inc.	1.1%	1.3%	1,447,310	-21.3%	$47.0M
IPSCCentury Therapeutics Inc	1.0%	1.1%	17,754,430	+0.0%	$43.4M
TECXTectonic Therapeutic Inc	1.0%	1.1%	1,204,891	+0.0%	$41.4M
XNCRXencor Inc	0.9%	0.8%	2,452,138	+0.0%	$39.5M
SRZNSurrozen Inc	0.9%	1.2%	1,473,101	+0.0%	$38.2M
EDITEditas Medicine Inc	0.9%	New	11,111,111	—	$36.0M
MBXMbx Biosciences Inc	0.9%	0.6%	650,000	+0.0%	$35.9M
PHVSPharvaris N V	0.8%	New	1,008,229	—	$34.9M
SLNSilence Therapeutics PLC	0.8%	0.5%	3,033,560	+0.0%	$33.3M
N44821101Inflarx NV	0.8%	New	14,500,000	—	$32.5M
ALTAltimmune Inc	0.7%	New	10,000,000	—	$30.4M
JANXJanux Therapeutics Inc	0.7%	0.7%	1,789,617	+0.0%	$27.5M
CATXPerspective Therapeutics Inc	0.6%	0.9%	7,915,567	+0.0%	$27.0M
AGMBAgomab Therapeutics NV	0.6%	0.6%	2,053,233	+0.0%	$26.7M
BHVNBiohaven Ltd	0.6%	1.1%	1,779,952	-61.6%	$26.5M
AKTSAktis Oncology Inc	0.5%	New	696,560	—	$22.5M
ALECAlector, Inc.	0.5%	0.6%	10,000,000	+0.0%	$20.1M
FBRXForte Biosciences Inc	0.5%	New	920,000	—	$19.6M
MNPRMonopar Therapeutics Inc	0.5%	0.2%	203,327	+53.9%	$18.8M
OCULOcular Therapeutix Inc	0.4%	0.4%	1,647,752	+0.0%	$16.2M
ADCTAdc Therapeutics SA	0.3%	1.2%	11,390,175	+0.0%	$12.2M
ALXOAlx Oncology Hldgs Inc	0.3%	0.7%	5,655,487	-56.5%	$11.7M
TRDAEntrada Therapeutics Inc	0.2%	0.8%	1,060,230	-53.7%	$7.8M
CGEMCullinan Therapeutics Inc	0.2%	0.2%	406,786	+0.0%	$7.4M
ARVNArvinas Inc	0.1%	0.7%	707,098	-70.4%	$5.9M
KRROKorro Bio Inc	0.1%	0.1%	416,301	+0.0%	$5.5M
RACCResearch Alliance Corp III	0.1%	New	500,000	—	$5.3M

What TCG Crossover Management, LLC bought and sold in Q2 2026, against Q1 2026.

Share counts compared with the Q1 2026 13F; a split also changes share counts. The latest filing lists more than 50 positions, so a position that left the top 50 may still be held.

How the holdings did against the S&P 500.

1 year: +136.6% /yr; S&P 500 +20.1%
3 years: +69.9% /yr; S&P 500 +21.8%
5 years: +86.4% /yr; S&P 500 +17.4%

A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.

Reported 13F value by quarter.

13F value by quarter
Quarter	13F value	Positions
Q2 2026	$4.2B	54
Q1 2026	$3.5B	49
Q4 2025	$3.0B	43
Q3 2025	$2.0B	40
Q2 2025	$875.5M	37
Q1 2025	$733.1M	37
Q4 2024	$1.0B	38
Q3 2024	$1.2B	36
Q2 2024	$959.5M	32
Q1 2024	$1.3B	33
Q4 2023	$901.7M	29
Q3 2023	$679.1M	26

Questions about TCG Crossover Management, LLC's portfolio

What stocks does TCG Crossover Management, LLC own?

TCG Crossover Management, LLC's latest 13F, for Q2 2026 and filed Aug 14, 2026, lists 54 positions worth $4.2B. The largest are Abivax SA (ABVX) at 19.2%, Tango Therapeutics Inc (TNGX) at 6.8%, Cg Oncology Inc (CGON) at 6.3%, Cogent Biosciences Inc (COGT) at 4.5% and Immunovant Inc (IMVT) at 4.1%.

What did TCG Crossover Management, LLC buy last quarter?

In Q2 2026, TCG Crossover Management, LLC added a new position in Zai Lab Ltd (ZLAB), a new position in Aura Biosciences Inc (AURA), a new position in First Tracks Biotherapeutics (TRAX), a new position in Editas Medicine Inc (EDIT), a new position in Pharvaris N V (PHVS), Avalo Therapeutics Inc (AVTX) (+308.6% shares) and Monopar Therapeutics Inc (MNPR) (+53.9% shares), compared with its Q1 2026 filing.

What did TCG Crossover Management, LLC sell last quarter?

In Q2 2026, TCG Crossover Management, LLC cut from its top 50 Centessa Pharmaceuticals PLC (CNTA), cut from its top 50 Fulcrum Therapeutics Inc (FULC), cut from its top 50 Liquidia Corporation (LQDA), cut from its top 50 Urogen Pharma Ltd (URGN), cut from its top 50 Context Therapeutics Inc (CNTX), Arvinas Inc (ARVN) (-70.4% shares), Biohaven Ltd (BHVN) (-61.6% shares) and Alx Oncology Hldgs Inc (ALXO) (-56.5% shares), compared with its Q1 2026 filing.

How has TCG Crossover Management, LLC's portfolio performed?

A portfolio copying TCG Crossover Management, LLC's 20 largest 13F holdings each quarter, from the day each filing was public, returned +69.9% a year over the last 3 years, against +21.8% for the S&P 500. Over 1 year: +136.6% against +20.1%. Over 5 years: +86.4% a year against +17.4%.

When is TCG Crossover Management, LLC's next 13F filing due?

13F filings are due 45 days after each quarter ends. TCG Crossover Management, LLC's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.

How much money does TCG Crossover Management, LLC manage?

TCG Crossover Management, LLC reported $5.1B of regulatory assets under management on its latest SEC Form ADV. Its 13F, which covers only US-listed stocks and options, totals $4.2B.